-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Haemonetics, Lowers Price Target to $70

Benzinga·03/11/2026 15:39:54
Listen to the news
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price target from $75 to $70.